Global Anti-Inflammatory Biologics Market Size Study & Forecast, by Drug Class (Anti-Tumor Necrosis Factor (TNF), Interleukin Antagonists, Janus Kinase (JAK) Inhibitors, and Others), By Application (Rheumatoid Arthritis, Psoriasis, and Others), By Route o

Global Anti-Inflammatory Biologics Market Size Study & Forecast, by Drug Class (Anti-Tumor Necrosis Factor (TNF), Interleukin Antagonists, Janus Kinase (JAK) Inhibitors, and Others), By Application (Rheumatoid Arthritis, Psoriasis, and Others), By Route of Administration (Oral and Injection), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Analysis, 2023-2030

Global Anti-Inflammatory Biologics Market is valued approximately at USD 93.13 billion in 2022 and is anticipated to grow with a growth rate of more than 5.9% over the forecast period 2023-2030. Anti-inflammatory biologics are advanced medications designed to target and reduce inflammation in the body, primarily used for treating conditions such as psoriasis, ulcerative colitis, rheumatoid arthritis and inflammatory bowel diseases has spurred demand for biologics. They work by interfering with specific molecules or pathways in the immune system, helping alleviate symptoms and prevent tissue damage. These biologics have transformed the treatment landscape for inflammatory conditions, offering relief to patients unresponsive to traditional therapies. The favorable reimbursement policies, rising aging population, increasing healthcare expenditure, and increased awareness of inflammation's are the most prominent factors that are propelling the market demand across the globe.

In addition, the surge in autoimmune inflammatory conditions such as psoriasis, rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases, and ulcerative colitis is a pivotal driver propelling market expansion. For instance, a study released by the NCBI in August 2021 reported a 3% prevalence of psoriasis among adults aged 20 years or older in the U.S., underlining the momentum in this arena. Likewise, according to the NCBI article published in September 2022, the incidence of rheumatoid arthritis in Northern Europe and Northern America was 24 and 36 cases per 100,000 people, respectively. Moreover, the swift adoption of biologics for treating inflammatory diseases and the favorable reimbursement landscape for biological therapies are poised to further bolster market advancement. Furthermore, the rise in investment in research activities for the development of biologics, as well as the growing advancements is biotechnology presents various lucrative opportunities over the forecasting years. However, the side effects of anti-inflammatory drugs and the lack of inclination for biologics as first line of treatment are hindering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Anti-Inflammatory Biologics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share owing to the surge in demand for anti-TNF drugs and promising pipeline candidates, serving as primary drivers propelling market growth. Furthermore, the strategic positioning of key players and robust sales of their pharmaceuticals in the region are anticipated to further bolster market expansion in North America. Whereas, Asia Pacific region is expected to grow the fastest over the forecast years. The increasing prevalence of diverse inflammatory disorders, rising healthcare spendings, and growing awareness regarding the available treatment options for these conditions are significantly propelling the market demand across the region.

Major market players included in this report are:
AbbVie Inc. (U.S.)
Merck & Co., Inc. (U.S.)
Bristol-Myers Squibb Company (U.S.)
Johnson & Johnson Services, Inc. (U.S.)
Pfizer Inc. (U.S.)
Novartis AG (Switzerland)
UCB S.A. (Belgium)
Eli Lilly and Company (U.S.)
Amgen Inc. (U.S.)
Biogen (U.S.)

Recent Developments in the Market:
 In February 2023, Pfizer Inc. revealed that the U.S. Food and Drug Administration (FDA) granted approval to its supplemental New Drug Application (sNDA) for CIBINQO, intended for patients grappling with moderate-to-severe atopic dermatitis.
 In March 2022, AbbVie announced the approval of RINVOQ (upadacitinib) by the U.S. Food and Drug Administration (FDA) for treating adults diagnosed with ulcerative colitis.
 In September 2022, Bristol Myers Squibb reported the two-year outcomes from the POETYK PSO Long-Term Extension (LTE) trial, focusing on sustained Sotyktu treatment in adult patients diagnosed with plaque psoriasis.
 In October 2022, GSK plc offered insights into the ContRAst phase III program concerning otilimab, an investigational monoclonal antibody aimed at potentially treating moderate to severe rheumatoid arthritis.

Global Anti-Inflammatory Biologics Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Drug Class, Route of Administration, Application, Distribution Channel, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Drug Class:
Anti-Tumor Necrosis Factor (TNF)
Interleukins Antagonists
Janus Kinase (JAK) Inhibitors
Others

By Route of Administration:
Oral
Injection

By Application:
Rheumatoid Arthritis
Psoriasis
Others

By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.